{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:44:16Z","timestamp":1790790256176,"version":"4.1.0"},"posted":{"date-parts":[[2023,10,5]]},"group-title":"Cardiovascular Medicine","reference-count":30,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,10,5]]},"abstract":"<jats:title>\n                  <jats:bold>Abstract<\/jats:bold>\n                <\/jats:title>\n                <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>In systemic light-chain (AL) amyloidosis, cardiac involvement portends poor prognosis. Using myocardial characteristics on magnetic resonance imaging (MRI), this study aimed to detect early myocardial alterations, to analyze temporal changes with plasma cell therapy, and to predict risk of major adverse cardiac events (MACE) in AL amyloidosis.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods and Results<\/jats:title>\n                  <jats:p>Participants with recently diagnosed AL amyloidosis were prospectively enrolled. Presence of AL cardiomyopathy (AL-CMP vs. AL-non-CMP) was determined by abnormal cardiac biomarkers. MRI was performed at baseline and 6 months, with 12-month imaging in AL-CMP cohort. MACE was defined as all-cause death, heart failure hospitalization, or cardiac transplantation. Mayo AL stage was based on troponin T, NT-proBNP, and difference in free light chains. The study cohort included 80 participants (median age 62 years, 58% males). Median left ventricular extracellular volume (ECV) was significantly higher in AL-CMP (53% vs. 30%, p&lt;0.001). ECV was abnormal (&gt;32%) in all AL-CMP and in 47% of AL-non-CMP. ECV tended to increase at 6 months and decreased significantly from 6 to 12 months in AL-CMP (median -3%, p=0.011). ECV was strongly associated with MACE (p&lt;0.001), and improved MACE prediction when added to Mayo AL stage (p=0.002). ECV\u226432% identified a cohort without MACE, while ECV&gt;48% identified a cohort with 74% MACE.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In AL amyloidosis, ECV detects subclinical cardiomyopathy. ECV tends to increase from baseline to 6 months and decreases significantly from 6 and 12 months of plasma cell therapy in AL-CMP. ECV provides excellent risk stratification and offers additional prognostic performance over Mayo AL stage.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.10.04.23296572","type":"posted-content","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:20:34Z","timestamp":1696537234000},"source":"Crossref","is-referenced-by-count":3,"title":["Myocardial Characterization for Early Diagnosis, Treatment Response Monitoring, and Risk Assessment in Systemic Light-Chain Amyloidosis"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-9318","authenticated-orcid":false,"given":"Olivier F.","family":"Clerc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A. M.","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jerosch-Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik C","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Katznelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Canseco Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Foley","family":"Kijewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo F.","family":"Di Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronglih","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023101012400585000_2023.10.04.23296572v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.053"},{"key":"2023101012400585000_2023.10.04.23296572v1.2","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-019-01760-6"},{"key":"2023101012400585000_2023.10.04.23296572v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.09.003"},{"key":"2023101012400585000_2023.10.04.23296572v1.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.016567"},{"key":"2023101012400585000_2023.10.04.23296572v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu444"},{"key":"2023101012400585000_2023.10.04.23296572v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.536"},{"issue":"1","key":"2023101012400585000_2023.10.04.23296572v1.7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12968-017-0419-6","article-title":"The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis","volume":"20","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"2023101012400585000_2023.10.04.23296572v1.8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/13506129.2019.1578742","article-title":"Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study","volume":"26","year":"2019","journal-title":"Amyloid"},{"key":"2023101012400585000_2023.10.04.23296572v1.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.112.978627"},{"key":"2023101012400585000_2023.10.04.23296572v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2017.02.012"},{"key":"2023101012400585000_2023.10.04.23296572v1.11","unstructured":"Martinez-Naharro A , Patel R , Kotecha T , Karia N , Ioannou A , Petrie A , et al. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022 Jul 28;ehac363."},{"issue":"9","key":"2023101012400585000_2023.10.04.23296572v1.12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","article-title":"Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET\/CT","volume":"60","year":"2019","journal-title":"J Nucl Med."},{"key":"2023101012400585000_2023.10.04.23296572v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.06.016"},{"key":"2023101012400585000_2023.10.04.23296572v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.02.025"},{"key":"2023101012400585000_2023.10.04.23296572v1.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04627-7"},{"key":"2023101012400585000_2023.10.04.23296572v1.16","unstructured":"Cuddy SAM , Jerosch-Herold M , Falk RH , Kijewski MF , Singh V , Ruberg FL , et al. Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC Cardiovasc Imaging. 2021 Dec 10;S1936-878X(21)00832-9."},{"key":"2023101012400585000_2023.10.04.23296572v1.17","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-019-01761-5"},{"key":"2023101012400585000_2023.10.04.23296572v1.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"2023101012400585000_2023.10.04.23296572v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.100"},{"key":"2023101012400585000_2023.10.04.23296572v1.20","doi-asserted-by":"publisher","DOI":"10.1186\/1532-429X-14-88"},{"key":"2023101012400585000_2023.10.04.23296572v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2012.04.006"},{"key":"2023101012400585000_2023.10.04.23296572v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2012.09.020"},{"key":"2023101012400585000_2023.10.04.23296572v1.23","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-020-00683-3"},{"key":"2023101012400585000_2023.10.04.23296572v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.10.011"},{"key":"2023101012400585000_2023.10.04.23296572v1.25","doi-asserted-by":"publisher","DOI":"10.1186\/s41512-018-0037-2"},{"key":"2023101012400585000_2023.10.04.23296572v1.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"},{"issue":"1","key":"2023101012400585000_2023.10.04.23296572v1.27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review","volume":"18","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2023101012400585000_2023.10.04.23296572v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2005.10.013"},{"key":"2023101012400585000_2023.10.04.23296572v1.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009039"},{"key":"2023101012400585000_2023.10.04.23296572v1.30","doi-asserted-by":"crossref","unstructured":"Gertz MA , Cohen AD , Comenzo RL , Kastritis E , Landau HJ , Libby EN , et al. Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. 2023 Jun 27;blood.2022019406.","DOI":"10.1182\/blood.2022019406"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.10.04.23296572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:42:31Z","timestamp":1768506151000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.10.04.23296572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1101\/2023.10.04.23296572","relation":{},"subject":[],"published":{"date-parts":[[2023,10,5]]},"subtype":"preprint"}}